$14.04
0.43% yesterday
Nasdaq, Nov 06, 10:00 pm CET
ISIN
US23306J1016
Symbol
DBVT

DBV Technologies SA Sponsored ADR Stock price

$14.04
+0.75 5.64% 1M
+4.65 49.52% 6M
+10.95 354.37% YTD
+10.19 264.68% 1Y
-0.96 6.40% 3Y
-7.56 35.00% 5Y
-353.76 96.18% 10Y
-214.96 93.87% 20Y
Nasdaq, Closing price Thu, Nov 06 2025
-0.06 0.43%
ISIN
US23306J1016
Symbol
DBVT
Industry

Key metrics

Basic
Market capitalization
$540.2m
Enterprise Value
$444.7m
Net debt
positive
Cash
$103.2m
Shares outstanding
136.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
142.2 | 7.1
EV/Sales
117.0 | 5.8
EV/FCF
negative
P/B
6.3
Financial Health
Equity Ratio
41.8%
Return on Equity
-416.7%
ROCE
-129.8%
ROIC
8,232.8%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$3.8m | $76.5m
EBITDA
$-116.5m | $-109.1m
EBIT
$-121.7m | $-135.7m
Net Income
$-122.6m | $-139.8m
Free Cash Flow
$-88.1m
Growth (TTM | estimate)
Revenue
-72.5% | 1,743.9%
EBITDA
-12.9% | 5.9%
EBIT
-31.7% | -16.5%
Net Income
-38.6% | -22.5%
Free Cash Flow
14.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-3,066.9% | -142.6%
EBIT
-3,203.2%
Net
-3,225.0% | -182.7%
Free Cash Flow
-2,318.7%
More
EPS
$-1.0
FCF per Share
$-0.6
Short interest
0.1%
Employees
110
Rev per Employee
$40.0k
Show more

Is DBV Technologies SA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

DBV Technologies SA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a DBV Technologies SA Sponsored ADR forecast:

6x Buy
75%
1x Hold
13%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a DBV Technologies SA Sponsored ADR forecast:

Buy
75%
Hold
13%
Sell
13%

Financial data from DBV Technologies SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3.80 3.80
72% 72%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 28 28
13% 13%
739%
- Research and Development Expense 96 96
13% 13%
2,524%
-117 -117
13% 13%
-3,067%
- Depreciation and Amortization 5.18 5.18
148% 148%
136%
EBIT (Operating Income) EBIT -122 -122
32% 32%
-3,203%
Net Profit -123 -123
39% 39%
-3,225%

In millions USD.

Don't miss a Thing! We will send you all news about DBV Technologies SA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DBV Technologies SA Sponsored ADR Stock News

Neutral
GlobeNewsWire
2 days ago
Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2 nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual ...
Neutral
GlobeNewsWire
3 days ago
Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr.
Neutral
GlobeNewsWire
7 days ago
Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”)...
More DBV Technologies SA Sponsored ADR News

Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Head office France
CEO Daniel Tassé
Employees 110
Founded 2002
Website www.dbv-technologies.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today